(Q44563397)

4 December 2017

title

Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity (English)

1 reference

4 December 2017

G M T Vogel

1

1 reference

4 December 2017

D G Meuleman

2

1 reference

4 December 2017

T G Van Dinther

3

1 reference

4 December 2017

R Buijsman

4

1 reference

4 December 2017

A W M Princen

5

1 reference

4 December 2017

M J Smit

6

1 reference

4 December 2017

language of work or name

1 reference

1 September 2003

1 reference

Journal of Thrombosis and Haemostasis

4 December 2017

published in

1 reference

4 December 2017

volume

1

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

1945-1954

1 reference

Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coron

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Direct thrombin inhibitors in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Direct thrombin inhibitors in acute coronary syndromes: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Inhibition of transforming growth factor-beta 2 expression with phosphorothioate antisense oligonucleotides in U937 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Persistent activation of coagulation mechanism in unstable angina and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00351.X

10.1046/J.1538-7836.2003.00351.X

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference